Growth index funds have charted a smoother start to 2023 than their value counterparts. Just how much smoother depends on the indexes in question.
SPDR Portfolio S&P 500 Growth ETF climbed 1.91% from January 2023 through March 13, 2023. That constituted success compared with its value twin, SPDR Portfolio S&P 500 Value ETF , which pulled back 0.53%. But next to Vanguard Growth ETF —a fellow large-growth index fund and reasonable alternative—it raises questions. VUG’s 7.07% gain over the same year-to-date span trounced SPYG and beat its own value counterpart, Vanguard Value ETF , by 11.79 percentage points.*
Discreet differences in index construction explain how the S&P value and growth index trackers ran neck-and-neck as the CRSP indexes that underpin VUG and VTV diverged. These index idiosyncrasies can drive different outcomes for investors, and they are most pronounced in the small-cap arena.
Nuances in Growth and Value Index Funds
Index providers build most style-oriented benchmarks by carving a broad universe of stocks, like the S&P 1500 Index, into different segments based on constituents’ size and style traits. Index providers differentiate themselves with distinct definitions of size and style. For example, the S&P 500 Growth Index leans larger because it chooses from 500 of the largest U.S. stocks, while the CRSP U.S. Large Cap Growth Index pulls from the market’s heftiest 85%—an approach that historically added about 50-150 companies beyond the largest 500.
Measuring style is more nuanced than size. Exhibit 1 illustrates how S&P and CRSP indexes define value and growth, with shared criteria bolded. Both index providers score firms on the listed criteria, routing those that represent the cheaper half of the universe to the value portfolio and the richer half to the growth index. Despite a few different style components, usually draw .
That said, the S&P indexes’ momentum feature can be a stylistic wild card. Momentum posits that the market’s recent outperformers will continue to outperform in the near term. That description often applies to growth stocks, but cheaper firms can check the momentum box during value rallies. Such was the case toward the end of 2022, when the cheapest stocks were many of the bear market’s most resilient.
The momentum component sparked a flurry of unusual index changes when the S&P indexes rebalanced in December 2022. SPYG cut exposure to the tech and consumer discretionary sectors, two of the worst performing sectors in 2022, by a combined 15 percentage points. It filled the void with stocks from top-performing sectors—healthcare, energy, and consumer staples—whose collective weight swelled from about 16% to 37% overnight. Exxon Mobil , Chevron , Johnson & Johnson , and Merck all entered the fray as top-20 holdings after previously residing in the value index. Meanwhile, VUG stood pat: None of its sector weights moved by more than 1.5 percentage points.
On the flip side of the rebalance, SPYV scooped up most of what SPYG discarded. Its tech and consumer discretionary exposure climbed by 10 combined percentage points as Microsoft , Amazon.com , and Meta cannonballed into the top-10 holdings. The fund halved its exposure to the healthcare, energy, and consumer staples firms that served as ballast in 2022. VTV welcomed Meta to its ranks, too, but no other addition or subtraction represented more than 0.2% of that portfolio.
The S&P indexes’ December shuffle has so far been disastrous for SPYG. The battered tech and consumer discretionary firms it sold have fared far better than the companies that replaced them. The fund has watched former holdings Meta and Salesforce power VUG and other growth peers with excellent 2023 rebounds. Meanwhile, newly boosted stakes in healthcare firms Pfizer , UnitedHealth Group , and Johnson & Johnson—all absent from VUG—sapped returns, as each firm lost between 12% and 22% for the year to date through March 13.
On the other hand, SPYG’s trash is SPYV’s treasure. Many of its new additions have flourished, while those it traded to its counterpart have floundered. That pushed SPYV well ahead of VTV, which didn’t unload the same stocks at its quieter December 2022 rebalance.
Down the Ladder
How index providers choose to gerrymander the stock universe by size and style leads to even more disparity between small-cap index strategies. At the end of January 2023, iShares S&P Small-Cap 600 Growth ETF and Vanguard Small-Cap Growth ETF shared only 11% of their portfolios. For investors seeking small-growth exposure, these two index funds—commonly misunderstood to be interchangeable measures of that market—offer entirely different portfolios.
Much of the difference owes to the index providers’ different definitions of “small cap.” S&P draws the border much lower than CRSP, leaving IJT with an average market capitalization about half the size of VBK. That proved to be a headwind early in 2023. IJT shed 1.86% for the year to date through March 13, 2023, trailing VBK by 4.56 percentage points.
IJT also trailed iShares S&P Small-Cap 600 Value ETF by 1.9 percentage points over that span. In this case, the S&P value index beat its growth counterpart in category-relative and absolute terms. A recent rebalancing is not to blame here, though. IJS has stayed above water in 2023 thanks to enormous returns from a select few longer-term holdings, like Myriad Genetics (purchased December 2018) and Cinemark (August 2021).
Thinking Long Term
Divergent performance between S&P’s and CRSP’s style indexes in 2023 is a reminder that . But it’s important to stay focused on the big picture. All of the ETFs mentioned in this piece earn Morningstar Analyst Ratings of Bronze or better because they are sensibly constructed, cheap, and backed by strong organizations. An ill-timed rebalance does not diminish these funds’ credibility.
Moreover, style definition nuances tend to wash out over time. VUG led SPYG by just 22 basis points annualized from its January 2004 inception through March 13, 2023, despite numerous stretches like early 2023. Falling behind its competitors does not always mean an index fund is in disarray. Oftentimes, the best action for these fundholders is to take no action at all.
* Vanguard also offers ETFs that track S&P style indexes. CRSP’s size and value/growth definitions do not reflect Vanguard’s view on how best to draw index borders, nor do S&P’s measurements reflect State Street’s view.
Carefully consider the investment objectives, risks, charges and expenses before investing. A prospectus, obtained by calling 800-669-3900, contains this and other important information about an investment company. Read carefully before investing.
A mutual fund is not FDIC-insured, may lose value, and is not guaranteed by a bank or other financial institution.
Performance quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance of the product over varying market conditions or economic cycles. Current performance may be lower or higher than the performance data quoted. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
TD Ameritrade receives remuneration from mutual fund companies, including those participating in its no-load, no-transaction-fee program, for recordkeeping, shareholder services, and other administrative and distribution services. The amount of TD Ameritrade's remuneration for these services is based in part on the amount of investments in such funds by TD Ameritrade clients. PLEASE ALSO SEE IMPORTANT ADDITIONAL FUND FEE DISCLOSURE INFORMATION
No-transaction-fee funds and other funds offered through TD Ameritrade have other fees and expenses that apply to a continued investment in the fund and are described in the prospectus.
Mutual funds, closed-end funds and exchange-traded funds are subject to market, exchange rate, political, credit, interest rate, and prepayment risks, which vary depending on the type of fund. International investments involve special risks, including currency fluctuations and political and economic instability. Asset allocation and diversification do not eliminate the risk of experiencing investment losses. Fund purchases may be subject to investment minimums, eligibility and other restrictions, as well as charges and expenses.
1You could lose money by investing in a money market fund.Although the fund seeks to preserve the value of your investment at $1 per share, it cannot guarantee it will do so.The fund may impose a fee upon the sale of your shares or may temporarily suspend your ability to sell shares if the fund's liquidity falls below required minimums because of market conditions or other factors. An investment in the fund is not insured or guaranteed by the FDIC or any other government agency. The fund's sponsor has no legal obligation to provide financial support to the fund, and you should not expect that the sponsor will provide financial support to the fund at any time.
2You could lose money by investing in a money market fund. Although the fund seeks to preserve the value of your investment at $1 per share, it cannot guarantee it will do so. An investment in the fund is not insured or guaranteed by the FDIC or any other government agency. The fund’s sponsor has no legal obligation to provide financial support to the fund, and you should not expect that the sponsor will provide financial support to the fund at any time.
3You could lose money by investing in a money market fund. Because the share price of the fund will fluctuate, when you sell your shares they may be worth more or less than what you originally paid for them. The fund may impose a fee upon the sale of your shares or may temporarily suspend your ability to sell shares if the fund's liquidity falls below required minimums because of market conditions or other factors. An investment in the fund is not insured or guaranteed by the FDIC or any other government agency. The fund's sponsor has no legal obligation to provide financial support to the fund, and you should not expect that the sponsor will provide financial support to the fund at any time.
Most mutual funds charge 2.00% on the redemption of shares (including by exchange) held for less than a certain number of calendar days. Performance figures reported do not reflect the deduction of this fee. If reflected, the fee would reduce the performance quoted. Please refer to the fund's prospectus for redemption fee information. TD Ameritrade may also charge its own short-term redemption fee.
TD AMERITRADE RISKS OF INVESTING IN FUNDS: PLEASE READ IMPORTANT ADDITIONAL MUTUAL FUND, EXCHANGE-TRADED FUND, AND CLOSED-END FUND RISK DISCLOSURES
Research and planning tools are obtained by unaffiliated third-party sources deemed reliable by TD Ameritrade. However, TD Ameritrade does not guarantee their accuracy and completeness and makes no warranties with respect to results to be obtained from their use. The Investment Profile report is for informational purposes only.
Mutual Funds: Commentary
Commentary
Growth index funds have charted a smoother start to 2023 than their value counterparts. Just how much smoother depends on the indexes in question.
SPDR Portfolio S&P 500 Growth ETF climbed 1.91% from January 2023 through March 13, 2023. That constituted success compared with its value twin, SPDR Portfolio S&P 500 Value ETF , which pulled back 0.53%. But next to Vanguard Growth ETF —a fellow large-growth index fund and reasonable alternative—it raises questions. VUG’s 7.07% gain over the same year-to-date span trounced SPYG and beat its own value counterpart, Vanguard Value ETF , by 11.79 percentage points.*
Discreet differences in index construction explain how the S&P value and growth index trackers ran neck-and-neck as the CRSP indexes that underpin VUG and VTV diverged. These index idiosyncrasies can drive different outcomes for investors, and they are most pronounced in the small-cap arena.
Nuances in Growth and Value Index Funds
Index providers build most style-oriented benchmarks by carving a broad universe of stocks, like the S&P 1500 Index, into different segments based on constituents’ size and style traits. Index providers differentiate themselves with distinct definitions of size and style. For example, the S&P 500 Growth Index leans larger because it chooses from 500 of the largest U.S. stocks, while the CRSP U.S. Large Cap Growth Index pulls from the market’s heftiest 85%—an approach that historically added about 50-150 companies beyond the largest 500.
Measuring style is more nuanced than size. Exhibit 1 illustrates how S&P and CRSP indexes define value and growth, with shared criteria bolded. Both index providers score firms on the listed criteria, routing those that represent the cheaper half of the universe to the value portfolio and the richer half to the growth index. Despite a few different style components, usually draw .
That said, the S&P indexes’ momentum feature can be a stylistic wild card. Momentum posits that the market’s recent outperformers will continue to outperform in the near term. That description often applies to growth stocks, but cheaper firms can check the momentum box during value rallies. Such was the case toward the end of 2022, when the cheapest stocks were many of the bear market’s most resilient.
The momentum component sparked a flurry of unusual index changes when the S&P indexes rebalanced in December 2022. SPYG cut exposure to the tech and consumer discretionary sectors, two of the worst performing sectors in 2022, by a combined 15 percentage points. It filled the void with stocks from top-performing sectors—healthcare, energy, and consumer staples—whose collective weight swelled from about 16% to 37% overnight. Exxon Mobil , Chevron , Johnson & Johnson , and Merck all entered the fray as top-20 holdings after previously residing in the value index. Meanwhile, VUG stood pat: None of its sector weights moved by more than 1.5 percentage points.
On the flip side of the rebalance, SPYV scooped up most of what SPYG discarded. Its tech and consumer discretionary exposure climbed by 10 combined percentage points as Microsoft , Amazon.com , and Meta cannonballed into the top-10 holdings. The fund halved its exposure to the healthcare, energy, and consumer staples firms that served as ballast in 2022. VTV welcomed Meta to its ranks, too, but no other addition or subtraction represented more than 0.2% of that portfolio.
The S&P indexes’ December shuffle has so far been disastrous for SPYG. The battered tech and consumer discretionary firms it sold have fared far better than the companies that replaced them. The fund has watched former holdings Meta and Salesforce power VUG and other growth peers with excellent 2023 rebounds. Meanwhile, newly boosted stakes in healthcare firms Pfizer , UnitedHealth Group , and Johnson & Johnson—all absent from VUG—sapped returns, as each firm lost between 12% and 22% for the year to date through March 13.
On the other hand, SPYG’s trash is SPYV’s treasure. Many of its new additions have flourished, while those it traded to its counterpart have floundered. That pushed SPYV well ahead of VTV, which didn’t unload the same stocks at its quieter December 2022 rebalance.
Down the Ladder
How index providers choose to gerrymander the stock universe by size and style leads to even more disparity between small-cap index strategies. At the end of January 2023, iShares S&P Small-Cap 600 Growth ETF and Vanguard Small-Cap Growth ETF shared only 11% of their portfolios. For investors seeking small-growth exposure, these two index funds—commonly misunderstood to be interchangeable measures of that market—offer entirely different portfolios.
Much of the difference owes to the index providers’ different definitions of “small cap.” S&P draws the border much lower than CRSP, leaving IJT with an average market capitalization about half the size of VBK. That proved to be a headwind early in 2023. IJT shed 1.86% for the year to date through March 13, 2023, trailing VBK by 4.56 percentage points.
IJT also trailed iShares S&P Small-Cap 600 Value ETF by 1.9 percentage points over that span. In this case, the S&P value index beat its growth counterpart in category-relative and absolute terms. A recent rebalancing is not to blame here, though. IJS has stayed above water in 2023 thanks to enormous returns from a select few longer-term holdings, like Myriad Genetics (purchased December 2018) and Cinemark (August 2021).
Thinking Long Term
Divergent performance between S&P’s and CRSP’s style indexes in 2023 is a reminder that . But it’s important to stay focused on the big picture. All of the ETFs mentioned in this piece earn Morningstar Analyst Ratings of Bronze or better because they are sensibly constructed, cheap, and backed by strong organizations. An ill-timed rebalance does not diminish these funds’ credibility.
Moreover, style definition nuances tend to wash out over time. VUG led SPYG by just 22 basis points annualized from its January 2004 inception through March 13, 2023, despite numerous stretches like early 2023. Falling behind its competitors does not always mean an index fund is in disarray. Oftentimes, the best action for these fundholders is to take no action at all.
* Vanguard also offers ETFs that track S&P style indexes. CRSP’s size and value/growth definitions do not reflect Vanguard’s view on how best to draw index borders, nor do S&P’s measurements reflect State Street’s view.
Profitable Lessons From the Bad Timing of Other Investors
U.S. Fund Flows: Widespread Outflows Defined March
U.S. Government’s Investment Options Good but Could Be Great
May ETF Flows Favor Recent Winners from Divergent Stock Market
How Do Your State’s 529 Tax Benefits Stack Up?
Bracing for Breakthroughs
Investing in Times of Climate Change 2023
Mastering Multifactor Funds
How Can Active Stock Managers Improve Their Funds’ Performance? By Taking a Vacation—a Long One
Why This BlackRock Allocation Fund Earned an Upgrade
3rd Party Research Disclosure /public-12:58:56
Market Data Disclosure